NCT00796276View on ClinicalTrials.gov

A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release Paliperidone

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2004

Study Completion Date

August 31, 2004

Conditions
Schizophrenia
Interventions
DRUG

IR OROS paliperidone and ER OROS paliperidone

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00796276 - A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release Paliperidone | Biotech Hunter | Biotech Hunter